Positive HAS opinions for reimbursement of several services in France in June 2024

On June 10, 2024, the French National Authority for Health (HAS) published its positive opinions regarding the registration of the destruction of one or more desmoid tumors by cryoablation, transcutaneously, with CT guidance and MRI guidance in the CCAM Nomenclature (level II of clinical added value) under the following services:

• "Destruction of one or more desmoid tumors by cryoablation, transcutaneously, with MRI guidance”;
• "Destruction of one or more desmoid tumors by cryoablation, transcutaneously, with CT guidance”. 

Also, on June 11, 2024, HAS published its positive opinion on the extension of the indication for the NABM services of detection of the genomes of influenza A and B viruses and SARS-CoV-2 by RT-PCR for patients reporting risky exposure to a zoonotic influenza virus and presenting symptoms compatible with infection by the SARS-CoV-2 virus or a winter respiratory infection, including influenza, to whatever the time of year (level III of Clinical Added Value, ASA).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.